Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

BACKGROUND: Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or without obinutuzumab against chlorambucil with obinutuzumab in patients with treatment-naive chronic lymphocytic leukae...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet
Hlavní autoři: Sharman, Jeff P, Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Pagel, John M, Flinn, Ian W, Kamdar, Manali, Munir, Talha, Walewska, Renata, Corbett, Gillian, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Coutre, Steven, Follows, George, Walker, Patricia, Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Woyach, Jennifer A, Salles, Gilles, Wierda, William G, Izumi, Raquel, Munugalavadla, Veerendra, Patel, Priti, Wang, Min Hui, Wong, Sofia, Byrd, John C
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8151619/
https://ncbi.nlm.nih.gov/pubmed/32305093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(20)30262-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky